Lipfendra Approval: The First Oral PCSK9 Inhibitor
FDA approved once-daily enlicitide, sold as Lipfendra, as an addition to diet and exercise for lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
Timeline
- Before 2026: Approved PCSK9-targeting medicines were available as injections.
- July 17, 2026: FDA approved Lipfendra as the first oral PCSK9 inhibitor.
- At approval: The label recommended one 20-milligram tablet daily under specific fasting instructions.
The US Food and Drug Administration approved Lipfendra, the brand name for enlicitide, on July 17, 2026. It is used with diet and exercise to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The medicine is the first approved PCSK9 inhibitor taken by mouth rather than injection. [1][2]
PCSK9 is a protein that promotes breakdown of LDL receptors on liver cells. Those receptors remove LDL cholesterol from blood. By blocking PCSK9 from interacting with the receptors, enlicitide allows more receptors to remain available and clear LDL. The mechanism is related to injectable antibody PCSK9 inhibitors, while the dosage form and molecular design differ. [1][2]
FDA evaluated two randomized, double-blind, placebo-controlled trials with 3,207 adults already receiving maximally tolerated statin therapy. One enrolled people with established atherosclerotic cardiovascular disease or high risk, and the other enrolled people with heterozygous familial hypercholesterolemia. The primary comparison was percentage change in LDL cholesterol from baseline to week 24. [1]
In the broader high-risk trial, FDA reported an average 56 percent LDL reduction relative to placebo at week 24. In the inherited-cholesterol trial, the average reduction was 59 percent. These values measure cholesterol lowering, not a direct trial result for heart attacks or strokes, and an individual's response may differ from the group average. [1]
The label recommends one 20-milligram tablet each morning on an empty stomach with water, black coffee or plain tea, followed by at least 30 minutes before other food or drink. The tablet should be swallowed whole. These instructions matter because food can reduce exposure and the LDL-lowering effect; patients should follow the current label and prescriber's directions. [2]
Adverse-reaction frequency in the first trial was similar for Lipfendra and placebo. In the heterozygous familial hypercholesterolemia trial, diarrhea and dizziness occurred more often with Lipfendra. Trial rates do not capture every possible post-approval effect, so clinicians still review other medicines, health conditions, laboratory goals and tolerability during ongoing care. [1][2]
Lipfendra expands PCSK9 treatment from injections to a daily oral option; it does not make injections, statins or other medicines obsolete. Its approved role is to lower LDL alongside diet and exercise in adults meeting the indication. Choice of therapy depends on the amount of additional lowering needed, adherence, cost, side effects and a clinician's assessment of cardiovascular risk. [1][2]
Sources
- FDA — First oral PCSK9 inhibitor approved to lower LDL cholesterol
- FDA — Lipfendra prescribing information